These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33496313)

  • 1. Lessons from COLCOT and LoDoCo2: colchicine for secondary prevention in coronary artery disease.
    Bouabdallaoui N; Blondeau L; Tardif JC
    Eur Heart J; 2021 Jul; 42(28):2800-2801. PubMed ID: 33496313
    [No Abstract]   [Full Text] [Related]  

  • 2. Colchicine in the Management of Acute and Chronic Coronary Artery Disease.
    Bouabdallaoui N; Tardif JC
    Curr Cardiol Rep; 2021 Jul; 23(9):120. PubMed ID: 34269908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2).
    Samuel M; Tardif JC
    Future Cardiol; 2021 May; 17(3):411-414. PubMed ID: 33687270
    [No Abstract]   [Full Text] [Related]  

  • 4. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
    Nidorf SM; Fiolet ATL; Eikelboom JW; Schut A; Opstal TSJ; Bax WA; Budgeon CA; Tijssen JGP; Mosterd A; Cornel JH; Thompson PL;
    Am Heart J; 2019 Dec; 218():46-56. PubMed ID: 31706144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colchicine for the treatment of coronary artery disease.
    Aimo A; Pascual-Figal DA; Barison A; Cediel G; Vicente ÁH; Saccaro LF; Emdin M; Bayes-Genis A
    Trends Cardiovasc Med; 2021 Nov; 31(8):497-504. PubMed ID: 33096241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging evidence for the use of colchicine for secondary prevention of coronary heart disease.
    Nidorf SM; Layland J; Robinson PC; Patel S; Psaltis PJ; Thompson PL
    Med J Aust; 2022 May; 216(8):385-387. PubMed ID: 35393699
    [No Abstract]   [Full Text] [Related]  

  • 8. Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians.
    Marquis-Gravel G; Goodman SG; Anderson TJ; Bell AD; Bewick D; Cox J; Grégoire JC; Gupta A; Huynh T; Kertland H; Kouz S; L'Allier PL; Madan M; Mancini GBJ; McPherson R; So DYF; Welsh RC; Wong G; Tardif JC
    Can J Cardiol; 2021 Nov; 37(11):1837-1845. PubMed ID: 34418482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies.
    Banach M; Penson PE
    Curr Atheroscler Rep; 2021 May; 23(7):32. PubMed ID: 33970350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review.
    Zhang FS; He QZ; Qin CH; Little PJ; Weng JP; Xu SW
    Acta Pharmacol Sin; 2022 Sep; 43(9):2173-2190. PubMed ID: 35046517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colchicine in coronary artery disease.
    Katira A; Katira R
    Postgrad Med J; 2022 Sep; 98(1163):718-721. PubMed ID: 33782205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colchicine in Stable Coronary Artery Disease.
    Fiolet ATL; Nidorf SM; Mosterd A; Cornel JH
    Clin Ther; 2019 Jan; 41(1):30-40. PubMed ID: 30396516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Inflammatory Hypothesis of Coronary Artery Disease.
    Boland J; Long C
    Curr Cardiol Rep; 2021 Jan; 23(2):6. PubMed ID: 33409720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Colchicine in patients with coronary heart disease : LoDoCo2 trial].
    Koenig W; Nitschmann S
    Internist (Berl); 2021 Mar; 62(3):333-336. PubMed ID: 33580309
    [No Abstract]   [Full Text] [Related]  

  • 15. Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease.
    Xia M; Yang X; Qian C
    Am J Cardiol; 2021 Feb; 140():33-38. PubMed ID: 33137319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
    Bouabdallaoui N; Tardif JC; Waters DD; Pinto FJ; Maggioni AP; Diaz R; Berry C; Koenig W; Lopez-Sendon J; Gamra H; Kiwan GS; Blondeau L; Orfanos A; Ibrahim R; Grégoire JC; Dubé MP; Samuel M; Morel O; Lim P; Bertrand OF; Kouz S; Guertin MC; L'Allier PL; Roubille F
    Eur Heart J; 2020 Nov; 41(42):4092-4099. PubMed ID: 32860034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-Dose Colchicine for the Management of Coronary Artery Disease.
    Tardif JC; Marquis-Gravel G
    J Am Coll Cardiol; 2021 Aug; 78(9):867-869. PubMed ID: 34446157
    [No Abstract]   [Full Text] [Related]  

  • 18. Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis.
    Katsanos AH; Palaiodimou L; Price C; Giannopoulos S; Lemmens R; Kosmidou M; Georgakis MK; Weimar C; Kelly PJ; Tsivgoulis G
    Eur J Neurol; 2020 Jun; 27(6):1035-1038. PubMed ID: 32134555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Colchicine treatment after myocardial infarction : Colchicine Cardiovascular Outcomes Trial (COLCOT)].
    Klingenberg R; Nitschmann S
    Internist (Berl); 2020 Jul; 61(7):766-769. PubMed ID: 32103281
    [No Abstract]   [Full Text] [Related]  

  • 20. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
    Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC
    Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.